Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 11 , ISSUE 2 ( July-December, 2021 ) > List of Articles

SHORT COMMUNICATION

Increased Self-medication with Steroids in Inflammatory Bowel Disease Patients during COVID-19 Pandemic: Time to Optimize Specialized Telemonitoring Services

Gautam Vinay

Keywords : COVID-19, Inflammatory bowel diseases, Self-medication, Telemedicine

Citation Information : Vinay G. Increased Self-medication with Steroids in Inflammatory Bowel Disease Patients during COVID-19 Pandemic: Time to Optimize Specialized Telemonitoring Services. Euroasian J Hepatogastroenterol 2021; 11 (2):103-104.

DOI: 10.5005/jp-journals-10018-1342

License: CC BY-NC 4.0

Published Online: 22-10-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Inflammatory bowel disease (IBD) is a serious condition characterized by a complex interaction of genetic, environmental, and inflammatory variables that affect the gut and other extragastrointestinal systems. Self-medication with steroids has become a major issue in light of the current pandemic situation in IBD patients. We observed a higher frequency of steroid self-medication (17.9%) and steroid overprescription (28.2%) by non-gastroenterologists during the pandemic. The use of telemonitoring tools can improve patient-IBD care provider communications in terms of drug compliance and better disease outcomes.


PDF Share
  1. Derikx L, Lantinga MA, de Jong DJ, et al. Clinical outcomes of covid-19 in patients with inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis 2021;15(4):529–539. DOI: 10.1093/ecco-jcc/jjaa215.
  2. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020;159(2):481–491.e3. DOI: 10.1053/j.gastro.2020.05.032.
  3. Singh AK, Jena A, Kumar MP, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J 2021;9(2):159–176. DOI: 10.1177/2050640620972602.
  4. Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017;39(11):2216–2229. DOI: 10.1016/j.clinthera.2017.09.011.
  5. Chhaya V, Saxena S, Cecil E, et al. Steroid dependency and trends in prescribing for inflammatory bowel disease – a 20-year national population-based study. Aliment Pharmacol Ther 2016;44(5): 482–494. DOI: 10.1111/apt.13700.
  6. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn's Colitis 2017;11(6):649–670. DOI: 10.1093/ecco-jcc/jjx008.
  7. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohn's Colitis 2019;14(1): 4–22. DOI: 10.1093/ecco-jcc/jjz180.
  8. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 2020;34(6):1503–1511. DOI: 10.1038/s41375-020-0848-3.
  9. World Health O. Guidelines for the regulatory assessment of medicinal products for use in self-medication. Geneva: World Health Organization; 2000.
  10. Filipe V, Allen PB, Peyrin-Biroulet L. Self-medication with steroids in inflammatory bowel disease. Dig Liver Dis 2016;48(1):23–26. DOI: 10.1016/j.dld.2015.10.010.
  11. Mesonero Gismero F, Rodriguez-Lago I, Cañas M, et al. P571 self-medication with steroids in ulcerative colitis: results of a patient survey. J Crohn's Colitis 2020;14(Supplement_1):S480–S481. DOI: 10.1093/ecco-jcc/jjz203.699.
  12. Mesonero F, Juliá B, Saldaña R, et al. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients’ behaviors. Eur J Gastroenterol Hepatol 2021;33(4). DOI: 10.1097/MEG.0000000000001931.
  13. Quinn CC, Chard S, Roth EG, et al. The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants’ perceptions. J Med Internet Res 2019;21(6):e14165. DOI: 10.2196/14165.
  14. Pinto S, Loddo E, Paba S, et al. Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic. J Patient Rep Outcomes 2021;5(1):48. DOI: 10.1186/s41687-021-00323-z.
  15. Del Hoyo J, Nos P, Faubel R, et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. J Med Internet Res 2018;20(11):e11602. DOI: 10.2196/11602.
  16. Abutaleb A, Buchwald A, Chudy-Onwugaje K, et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflamm Bowel Dis 2018;24(10):2191–2197. DOI: 10.1093/ibd/izy149.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.